Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns - 2Find Successful Magnificence Items for Sparkling Skin
- 3Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
- 410 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- 5Pick Your Favored kind of sandwich
- Best Getaway destination: Ocean side, Mountain, or City
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- Brazil expands pesticide packaging reverse logistics
- The Most Notable Design Brands of the 21st Hundred years
- Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
- Dental Embed Developments: Upsetting Current Dentistry
- CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems
- ‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
